Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)

The summary for the Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed): The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune systemdevelopment patterns between two or more age groups- neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on ontogeny and development of pediatric immune system, from birth, transitioning into adolescence and adulthood with focus impact during pregnancy and post-natal period.

Federal Grant Title:	Pediatric Immune System Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-21-248
Type of Funding:	Grant
CFDA Numbers:	93.865
CFDA Descriptions:	Information not provided
Current Application Deadline:	May 7th, 2024
Original Application Deadline:	May 7th, 2024
Posted Date:	July 9th, 2021
Creation Date:	July 9th, 2021
Archive Date:	June 12th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 21st, 2022

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-21-248.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allo...; • National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 C...; • Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescen...; • Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed); • Biological Testing Facility (X01 Clinical Trial Not Allowed); • Phase II Small Business Technology Transfer Renewal Awards for Device Assessment or Precli...; • Phase II Small Business Innovation Research Renewal Awards for Device Assessment or Precli...; • Reproductive Genetics and Epigenetics
More Grants from the National Institutes of Health: • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required); • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional); • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)